Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-11-11

Clinical Trial Update: Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis [Phase 4]

View source ↗

Summary

Phase 4 trial updating intravenous dose optimization of vedolizumab in ulcerative colitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vedolizumab (vedolizumab)

Snippet

Sponsor: Takeda | Conditions: Colitis, Ulcerative | Phase 4 | Status: COMPLETED | Results posted: 2021-11-11